Young Sung - Genexine Chairman Founder

095700 Stock  KRW 5,900  60.00  1.03%   

Insider

Young Sung is Chairman Founder of Genexine
Age 67
Phone82 3 1628 3200
Webhttps://www.genexine.com

Genexine Management Efficiency

The company has return on total asset (ROA) of (0.0172) % which means that it has lost $0.0172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.0578) %, meaning that it generated substantial loss on money invested by shareholders. Genexine's management efficiency ratios could be used to measure how well Genexine manages its routine affairs as well as how well it operates its assets and liabilities.
Genexine has accumulated 40.79 B in total debt with debt to equity ratio (D/E) of 31.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genexine has a current ratio of 2.21, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genexine until it has trouble settling it off, either with new capital or with free cash flow. So, Genexine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genexine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genexine to invest in growth at high rates of return. When we think about Genexine's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

INSIDER Age

HeeSeok JooMedy Tox
57
Jaecheon LeeABL Bio
N/A
Jong WonABL Bio
N/A
WooSun LeeMedy Tox
46
SeungBum ParkMedy Tox
54
Jung KimABL Bio
N/A
KiHyuk YangMedy Tox
54
Jong KimABL Bio
N/A
Sang LeeABL Bio
N/A
YongIn KimMedy Tox
61
Lopez MichaelMedy Tox
62
Jae JungABL Bio
N/A
You WeonKyooABL Bio
N/A
HyunHo JungMedy Tox
61
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea. Genexine (095700) is traded on KOSDAQ in Korea and employs 123 people.

Management Performance

Genexine Leadership Team

Elected by the shareholders, the Genexine's board of directors comprises two types of representatives: Genexine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genexine. The board's role is to monitor Genexine's management team and ensure that shareholders' interests are well served. Genexine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genexine's outside directors are responsible for providing unbiased perspectives on the board's policies.
You Suh, Head Director
Jungwon Woo, Chief Officer
Sung CPA, CFO VP
Kyu Kim, Ex Bus
Jae Park, Ex Operation
Young Sung, Chairman Founder
JaiHyun Kwon, Director Transaction
Sung Lee, Head VP

Genexine Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genexine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Genexine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genexine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genexine will appreciate offsetting losses from the drop in the long position's value.

Moving against Genexine Stock

  0.43215600 SillaJenPairCorr
The ability to find closely correlated positions to Genexine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genexine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genexine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genexine to buy it.
The correlation of Genexine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genexine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genexine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genexine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Genexine Stock

Genexine financial ratios help investors to determine whether Genexine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genexine with respect to the benefits of owning Genexine security.